Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs.
Although intra-arterial radiotherapy with (131)I-labelled lipiodol is a useful therapeutic approach in the treatment of hepatocellular carcinomas, various disadvantages limit its use. Here we describe the development of (188)Re-SSS lipiodol, as well as its biodistribution in the healthy pig after injection into the hepatic artery. The (188)Re-SSS lipiodol was obtained after dissolving a chelating agent, previously labelled with (188)Re, in cold lipiodol. The radiochemical purity (RCP) of the labelling was checked immediately and at 24 and 48 h. The (188)Re-SSS lipiodol was injected into the hepatic artery of six healthy pigs. They were killed 1, 24 and 48 h post injection, for ex vivo counting. An autoradiographic study was performed in three cases. (188)Re-SSS lipiodol was obtained with a yield of 87%+/-9.1%. The immediate RCP was 93%+/-3.4%. This radiolabelling was reproducible and stable at 48 h in plasma: 90.6%+/-1.5% of the activity remained in the lipiodol with an RCP of 91%+/-4%. Ex vivo counting confirmed the predominantly hepatic uptake and revealed weak lung and intestinal uptake. There was very weak urinary elimination (2.3%+/-0.5% at 48 h) and a slightly higher level of intestinal elimination (4.8%+/-1.9% at 48 h). The autoradiographic studies showed (188)Re-SSS lipiodol to be located mainly in sinusoids, like (131)I-lipiodol. By using the method described here, (188)Re-SSS lipiodol can be obtained with a very high yield and a satisfactory RCP. Its biodistribution in the healthy pig is in agreement with data published elsewhere concerning other types of radiolabelling used for lipiodol, except for the very weak urinary and intestinal elimination, which probably indicates better stability of (188)Re-SSS labelling.
Garin
E
E
Service de Médecine Nucléaire, Centre Eugène Marquis, Rue de la bataille Flandes-Dunkerque, CS 44229, 35042 Rennes cedex, France. etienne.garin@univ-rennes1.fr
Noiret
N
N
Malbert
C
C
Lepareur
N
N
Roucoux
A
A
Caulet-Maugendre
S
S
Moisan
A
A
Lecloirec
J
J
Herry
J Y
JY
Bourguet
P
P
D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy; D004338:Drug Combinations; D005240:Feasibility Studies; D006499:Hepatic Artery / Q000378:metabolism*; D007278:Injections, Spinal; D007459:Iodized Oil / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D007553:Isotope Labeling / Q000379:methods; D008099:Liver / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000378:metabolism*; D008113:Liver Neoplasms / Q000532:radiotherapy; D008657:Metabolic Clearance Rate; D009928:Organ Specificity; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000138:chemical synthesis / Q000493:pharmacokinetics; D013552:Swine; D014018:Tissue Distribution
D004338:Drug Combinations; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C494618:rhenium-SSS-lipiodol; D007459:Iodized Oil